Neoadjuvant triple therapy for liver cancer

Neoadjuvant Transcatheter Arterial Chemoembolization Combined With Lenvatinib Plus Cadonilimab for Resectable Hepatocellular Carcinoma: A Single-Arm Phase II Clinical Trial

This study is testing a new combination treatment for liver cancer to see if it helps patients before they have surgery.

Quick facts

• Study type: Observational
• Enrollment: 20 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Fujian Provincial Hospital (Academic / other)
• Drugs / interventions: cadonilimab, lenvatinib, chemotherapy, camrelizumab
• Locations: 6 sites (Fuzhou, Fujian and 5 other locations)
• Trial ID: NCT06569498 on ClinicalTrials.gov

What this trial studies

This observational study evaluates the efficacy and safety of a combination treatment involving transarterial chemoembolization (TACE), lenvatinib, and camrelizumab in patients with resectable hepatocellular carcinoma (HCC). It is a single-arm, multi-center trial that aims to enroll 20 patients and assess primary endpoints such as major pathological response rate and safety. Secondary endpoints include recurrence-free survival, objective response rate, R0 resection rate, and overall survival. The study is designed to provide insights into the effectiveness of this triple therapy approach before surgical resection.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 75 with Child-Pugh class A liver function and resectable hepatocellular carcinoma.

Not a fit: Patients with severe comorbidities or those with Child-Pugh class B or C liver function may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve surgical outcomes and survival rates for patients with resectable HCC.

How similar studies have performed: While this approach is innovative, similar studies combining targeted therapies and embolization techniques have shown promise in other contexts.

Eligibility criteria

Inclusion Criteria:

1. Voluntarily join the study and sign the informed consent form.
2. Male or female patients aged between 18 and 75 years.
3. Child-Pugh class A.
4. Indocyanine green 15-minute retention rate (ICGR-15) \< 15%.
5. ECOG performance status 0-1.
6. Diagnosed with hepatocellular carcinoma (HCC) according to the "Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)."
7. BCLC stage A or B, with a single tumor larger than 5 cm or multiple tumors, and considered surgically resectable after multidisciplinary discussion.
8. According to RECIST 1.1 criteria, the patient has at least one measurable lesion (a measurable lesion with a long diameter ≥ 10 mm on CT/MRI scan, and the measurable lesion has not received local treatments such as radiotherapy or cryotherapy).
9. Blood routine: absolute neutrophil count ≥ 1.5 × 10\^9/L, Hb ≥ 8.5 g/L, PLT ≥ 75 × 10\^9/L.
10. No history of severe arrhythmia, heart failure, severe pulmonary ventilation disorders, or severe lung infections; no acute or chronic renal failure, and creatinine clearance rate \> 40 mL/min.
11. Women of childbearing potential must agree to use contraception during the medication period and for 6 months after the end of medication; have a negative serum or urine pregnancy test within 7 days prior to enrollment, and must not be breastfeeding. Men must agree to use contraception during the study period and for 6 months after the end of the study.

Exclusion Criteria:

1. Tumor rupture with bleeding or suspected abdominal cavity metastasis.
2. Previous treatment with any antitumor therapies before enrollment, such as targeted drugs, PD-1/PD-L1/CTLA-4 monoclonal antibodies, surgery, TACE, FOLFOX systemic chemotherapy, radiotherapy, and Huaier granules.
3. History of allergy to lenvatinib, cadonilimab, or their components.
4. Presence of any active autoimmune disease or a history of autoimmune disease with expected recurrence (e.g., interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes); hypothyroidism treated with stable doses of thyroid replacement hormone; type 1 diabetes mellitus treated with stable doses of insulin; excluding patients with vitiligo or childhood asthma/allergies that have resolved and require no intervention in adulthood.
5. History of immunodeficiency; patients using immunosuppressive drugs or systemic corticosteroids for immunosuppressive purposes and who have continued using them within 2 weeks before signing the informed consent form.
6. Known hereditary or acquired bleeding (e.g., coagulopathy) or thrombotic tendency, such as hemophilia; currently receiving or recently (within 10 days before the start of study treatment) receiving full-dose oral or injectable anticoagulants or thrombolytics for therapeutic purposes (prophylactic use of low-dose aspirin and low-molecular-weight heparin is allowed).
7. Severe infection within 4 weeks before the first use of the study drug (CTC AE grade \> 2), such as severe pneumonia requiring hospitalization, bacteremia, or infection complications; baseline chest imaging indicating active lung inflammation; symptoms and signs of infection within 2 weeks before the first use of the study drug or requiring oral or intravenous antibiotic treatment (excluding prophylactic antibiotic use).
8. Urinalysis indicating proteinuria ≥ 1+; if so, a 24-hour urine protein test is required; patients with 24-hour urine protein ≥ 1 g.
9. History of other malignancies within the past 5 years or concurrently, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid carcinoma.
10. Patients with concomitant psychiatric disorders; history of substance abuse, alcohol, or drug addiction.
11. Pregnant or breastfeeding women.
12. Patients with significant surgical contraindications, such as renal and cardiopulmonary insufficiency, as judged by the investigator, or any other reasons deemed unsuitable for participation in this trial by the investigator.

Where this trial is running

Fuzhou, Fujian and 5 other locations

• Fujian provincial hospital — Fuzhou, Fujian, China (Recruiting)
• First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (Not_yet_recruiting)
• Mengchao Hepatobiliary Hospital of Fujian Medical University — Fuzhou, Fujian, China (Not_yet_recruiting)
• Zhongshan Hospital of Xiamen University — Xiamen, Fujian, China (Not_yet_recruiting)
• First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China (Not_yet_recruiting)
• Zhangzhou Affiliated Hospital of Fujian Medical University — Zhangzhou, Fujian, China (Not_yet_recruiting)

Study contacts

• Study coordinator: Mao-Lin Yan

Conditions Resectable Hepatocellular Carcinoma